UBS Maintains Buy on Amgen, Raises Price Target to $420

Benzinga Newsdesk www.benzinga.com Positive 76.7%

Neg 0% Neu 0% Pos 76.7%

UBS analyst Michael Yee maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $400 to $420.

Comments

No comments yet. Be the first!